This report was first published by Endpoints News. To see the original version, click here
Amgen abruptly pulled out of a collaboration for a leading drug in its immunology pipeline on Friday, sending the asset back to its partner ahead of an FDA submission later this year.
Amgen terminated its partnership with Kyowa Kirin for rocatinlimab, the companies announced, which was being studied in eczema, asthma and other immunologic conditions. “This business decision is the result of a strategic portfolio prioritization by Amgen,” a Friday release states.
您已阅读14%（555字），剩余86%（3477字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。